NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

CorMedix Inc. (CRMD) Stock Analysis

CorMedix Inc. (CRMD) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

CRMD

$8.43

−$0.04 (−0.47%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CRMD with… →

CRMD Key Statistics

As of Sep 4, 2026
Trading
Open
$8.45
Previous Close
$8.47
Day's Range
8.31–8.61
52-Week Range
6.13–13.83
Volume
792.80K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.50
Valuation
Market Cap
$657.07M
P/E Ratio
3.88
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
24.09
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.42
EPS (ttm)Profit attributable to each share over the last twelve months.
2.17
Financials (FY)
Revenue (FY)
$311.71M+617.03%
Net Income (FY)
$163.06M
Profit marginThe share of revenue left as profit after all costs and taxes.
40.49%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
77.94M
1-Year Return
−34.14%
Dividend and dates
Earnings Date
November 16, 2026
Avg Volume
1.30M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CRMD Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−27.52%
2025+43.58%
2024+115.43%
2023−10.90%
2022−7.25%
2021−38.76%
2020+2.06%
2019+12.87%
2018+158.00%
2017−67.32%
2016 (partial year)+6.99%

As of September 4, 2026.

CRMD Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$311.71M$163.06M52.3%
2024$43.47M−$17.93M−41.2%
2023$0.00−$46.34M—
2022$65.41K−$29.70M−45409.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$311.71M$275.75M$150.14M$163.06M52.3%
2024$43.47M$40.28M−$22.36M−$17.93M−41.2%
2023$0.00$0.00−$48.96M−$46.34M—
2022$65.41K$61.67K−$30.62M−$29.70M−45409.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CRMD Valuation vs Biotechnology Median

Median of 656 stocks
MetricCRMDBiotechnology medianvs median
P/E3.8812.570.3x the median
P/S ratio1.4215.260.1x the median
Profit margin40.49%0.00%40.5 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 17 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

CorMedix Inc. (CRMD) is capitalised at $657.07M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 191 employees.

The 52-week range on file runs from $6.13 to $13.83. The most recent close on file for CRMD is $8.43, dated September 4, 2026. That is −$0.04 (−0.47%) against the previous close. The latest close sits 37.52% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $311.71M. Against the prior fiscal year total of $43.47M, that is a change of +617.03%. The same year closed with net income of $163.06M. The reported profit margin is 40.49%. That is 40.5 percentage points above the Biotechnology median of 0%. Trailing earnings per share are 2.17.

Across the 4 fiscal years on file, revenue moves from $65.41K in 2022 to $311.71M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 3.88. That is 0.3 times the Biotechnology median of 12.57. The forward P/E on file is 24.09. The price-to-sales ratio is 1.42. On price-to-sales that is 0.1 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned −34.14%. Across 10 years the annualized return works out at −0.82%. Beta against the wider market is reported at 1.5. Annualized volatility over the trailing 10 years is 92.04%.

Growth & Income

No dividend is on file for CRMD.

The strongest complete calendar year on file is 2018 at +158.00%; the weakest is 2017 at −67.32%. Of the 9 complete calendar years on file, 5 finished higher. 2026 is still running; the price is −27.52% year to date.

Peer Comparison

CorMedix Inc. (CRMD) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
CorMedix Inc. CRMD $657.07M 3.9
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. CorMedix Inc. trades at a P/E of 3.9.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About CorMedix Inc.

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.

Visit website →